Nicox’s Licensee Bausch + Lomb Secures Approval of VYZULTA® in Colombia
December 22, 2020
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Bausch + Lomb, has received approval for latanoprostene bunod ophthalmic solution, 0.024% (marketed as VYZULTA® In the United States) in Colombia, where it will be marketed under the brand name CLIROPTA®.
VYZULTA is currently commercialized in the United States, Canada and Argentina and approved in 5 other territories – Colombia, Hong Kong, Mexico, Taiwan and Ukraine – for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Bausch + Lomb will continue seeking approvals in territories where the clinical data package, part of the U.S. New Drug Application, can be used for approval by the regulatory authorities.
Under the terms of the exclusive license agreement with Bausch + Lomb, Nicox receives increasing tiered
royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestones
payments.
Bausch + Lomb is a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX:BHC).